Sumitomo Mitsui Trust Group Inc. Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sumitomo Mitsui Trust Group Inc. lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 32.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,764 shares of the medical equipment provider’s stock after purchasing an additional 2,127 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Lantheus were worth $784,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the third quarter valued at $25,000. Signaturefd LLC grew its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. UMB Bank n.a. grew its stake in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. RiverPark Advisors LLC purchased a new position in Lantheus during the third quarter valued at $74,000. Finally, CWM LLC lifted its position in Lantheus by 63.0% during the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 290 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of LNTH opened at $79.94 on Friday. Lantheus Holdings, Inc. has a 1-year low of $56.06 and a 1-year high of $126.89. The company has a 50-day moving average of $91.43 and a 200 day moving average of $97.79. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44.

Analyst Ratings Changes

Several research firms have commented on LNTH. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.